Humacyte jumps as U.S. legislation backs bioengineered vessels
Source: SeekingAlpha
2026-02-09 12:18:35 ET
More on Humacyte
- Humacyte, Inc. (HUMA) Q3 2025 Earnings Call Transcript
- Humacyte announces credit facility of $77.5M with Avenue Capital
- Humacyte outlines 12-month cash runway and accelerates Symvess adoption following $56.5M capital raise
- Seeking Alpha’s Quant Rating on Humacyte
- Historical earnings data for Humacyte
Read the full article on Seeking Alpha
For further details see:
Humacyte jumps as U.S. legislation backs bioengineered vessels
Humacyte Inc.
NASDAQ: HUMA
HUMA Trading
6.99% G/L:
$1.216 Last:
3,555,812 Volume:
$1.115 Open:
HUMA Latest News
February 18, 2026 08:00:00 am
Humacyte Announces Presentation of Symvess® Long-Term Safety and Efficacy Results at VESS Meeting
February 09, 2026 08:00:00 am
Humacyte Announces New U.S. Department of Defense Funding for Procurement of Bioengineered Blood Vessels
HUMA Stock Data
$220,166,898
198,988,939
0.6%
62
N/A
Biotechnology & Life Sciences
Healthcare
US
Durham
